Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-01-17 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2024年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a performance forecast announcement for the fiscal year 2024, providing estimated revenue and profit figures along with explanations for changes compared to the previous year. It explicitly states that the financial data are preliminary and unaudited, and that the final audited data will be disclosed in the formal 2024 annual report. The document length is short (1187 characters), and it serves as a forward-looking earnings preview rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, rather than a full Annual Report (10-K) or Interim Report (IR). FY 2024
2025-01-17 Chinese
深圳微芯生物科技股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details the changes in shareholding relationships among several parties, specifically the dissolution of a previously existing "一致行动关系" (concerted action or acting-in-concert relationship) among shareholders. The document includes detailed information about the shareholders, their shareholdings before and after the change, and confirms that the share quantities have not changed but the aggregation of shares for voting purposes has changed due to the dissolution of the concerted action agreement. It also references compliance with securities laws and disclosure obligations. There is no indication of financial results, earnings, management changes, or other report types. This type of document corresponds to a Major Shareholding Notification, which reports changes in significant share ownership levels or changes in concerted action relationships affecting control or voting power. The document is lengthy and detailed, not a mere announcement or certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is Major Shareholding Notification (MRQ).
2025-01-17 Chinese
深圳微芯生物科技股份有限公司重大事项内部报告制度（2025年1月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '重大事项内部报告制度' (Major Matters Internal Reporting System) issued by Shenzhen Microchip Biotechnology Co., Ltd. It outlines the procedures, responsibilities, and scope for internal reporting of major company matters that could affect stock price or company operations. The content includes definitions of reportable events, reporting obligations, confidentiality, and legal responsibilities. There are no financial statements, earnings data, or regulatory filings per se. It is not an announcement or a report of financial results, nor a proxy or voting result. It is a governance-related internal control document describing the company's internal reporting system for major events. Therefore, it fits best under Governance Information (CGR). The document length (7045 characters) and detailed procedural content support this classification with high confidence.
2025-01-15 Chinese
第三届董事会独立董事专门会议2025年第一次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of Shenzhen Microcore Biotechnology Co., Ltd. It discusses approval of the 2025 estimated daily related-party transaction limits and confirms compliance with relevant laws and company rules. There is no financial data, no mention of annual or interim reports, no earnings data, no voting results from a general meeting, and no mention of share transactions or capital changes. The document is a board/management announcement related to internal governance and board decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-01-15 Chinese
第三届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen Microchip Biotechnology Co., Ltd. It details the convening of the board meeting, attendance, and the voting results on various proposals such as related party transaction limits, extension of investment projects, appointment of a co-general manager, and revisions to internal management systems. The document does not contain financial statements or detailed financial analysis but focuses on board decisions and governance matters. It also references other announcements published separately on the stock exchange website. Given the content and focus on board meeting resolutions and management appointments, this document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2025-01-15 Chinese
关于收到《无效宣告请求受理通知书》的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the receipt of a 'Notice of Acceptance of Invalidity Declaration Request' from the National Intellectual Property Office of China. It details the status of a patent invalidity request filed against one of the company's patents, explaining the case background, current stage, and potential impact on the company. The document does not contain financial statements, earnings data, or detailed management analysis. It is a regulatory announcement about a legal/patent matter, specifically a legal proceeding update. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification, so RNS is less appropriate than LTR.
2025-01-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.